Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | CA3 | P07451 | 2/20 | 0.67 |
| ▸ | CA5A | P35218 | 2/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA4 | P22748 | 1/20 | 0.67 |
| ▸ | CA6 | P23280 | 1/20 | 0.67 |
| ▸ | CA7 | P43166 | 1/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316649 | 0.98 | MEN1 (0.79) | SMN1; SMN2ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL1000785 | 0.93 | ALDH1A1 (0.74) | SMN1; SMN2ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL27889238 | 0.89 | ALDH1A1 (1.00) | SMN1; SMN2ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL29982917 | 0.86 | MEN1 (1.00) | SMN1; SMN2ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL499036 | 0.84 | ALDH1A1 (0.65) | SMN1; SMN2ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL570465 | 0.80 | CA3 (0.91) | SMN1; SMN2ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL864397 | 0.80 | ALDH1A1 (0.82) | SMN1; SMN2ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL864398 | 0.80 | ALDH1A1 (0.82) | SMN1; SMN2ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL12936102 | 0.80 | CA3 (1.00) | SMN1; SMN2ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL10228415 | 0.80 | CA3 (1.00) | SMN1; SMN2ALDH1A1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090269734-A1 | METHOD FOR DETERMINATION OF RECOGNITION SPECIFICITY OF VIRUS FOR RECEPTOR SUGAR CHAIN | SHIZUOKA PREFECTURAL UNIVERSITIES CORPORATION, NATIONAL UNIVERSITY CORPORATION SHIZUOKA | 2009-10-29 | — | — | US | disclosed |
| US-20090181362-A1 | METHOD FOR DETERMINATION OF RECOGNITION SPECIFICITY OF VIRUS FOR RECEPTOR SUGAR CHAIN | NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITY (JP) | 2009-07-16 | — | — | US | disclosed |
| US-7223833-B1 | Peptide nucleic acid conjugates | ISIS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-0804456-B1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 2002-08-21 | — | — | EP | disclosed |
| US-6369101-B1 | Therapeutic method to treat herpes virus infection | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2002-04-09 | — | — | US | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| EP-0804456-A4 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998034603-A1 | USE OF BETULIN AND ANALOGS THEREOF TO TREAT HERPESVIRUS INFECTION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1998-08-13 | — | — | WO | disclosed |
| EP-0804456-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996011205-A9 | PEPTIDE NUCLEIC ACID CONJUGATES | — | 1996-05-30 | — | — | WO | disclosed |
| WO-1996011205-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181362-A1 | METHOD FOR DETERMINATION OF RECOGNITION SPECIFICITY OF VIRUS FOR RECEPTOR SUGAR CHAIN | SIGLEC7, SIGLEC9, NEU4 | SMN1; SMN2 2957/4885ALDH1A1 4034/4885POLB 3426/4885 |
| US-20090269734-A1 | METHOD FOR DETERMINATION OF RECOGNITION SPECIFICITY OF VIRUS FOR RECEPTOR SUGAR CHAIN | SIGLEC7, SIGLEC9, NEU4 | SMN1; SMN2 3154/4885ALDH1A1 4158/4885POLB 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.